AR087069A1 - Procesos e intermediarios para producir azaindoles - Google Patents
Procesos e intermediarios para producir azaindolesInfo
- Publication number
- AR087069A1 AR087069A1 ARP120102438A ARP120102438A AR087069A1 AR 087069 A1 AR087069 A1 AR 087069A1 AR P120102438 A ARP120102438 A AR P120102438A AR P120102438 A ARP120102438 A AR P120102438A AR 087069 A1 AR087069 A1 AR 087069A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- occurrences
- optionally substituted
- unsubstituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 6
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- -1 -NHCH3 Chemical group 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000008601 Polycythemia Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 abstract 1
- 206010028537 myelofibrosis Diseases 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052723 transition metal Inorganic materials 0.000 abstract 1
- 150000003624 transition metals Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
Abstract
La presente se refiere a procesos e intermediarios para la preparación de los compuestos útiles como inhibidores de las quinasas Janus (JAK). Estos compuestos son útiles en el tratamiento de dolencias tales como las enfermedades autoinmunes (alergia, asma), rechazo de transplantes, leucemia, linfomas, policitemia, trombocitemia esencial, mielofibrosis. Reivindicación 1: Un proceso para preparar un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, caracterizada porque: R¹ es -H, -Cl o -F; R² es -H o -F; R³ es -alifático C₁₋₄ opcionalmente sustituido con 1 - 5 ocurrencias de R⁵; R⁴ es -alquil C₁₋₂ opcionalmente sustituido con 1 - 3 ocurrencias de R⁵; o R³ y R⁴ se toman juntos para formar un anillo saturado carbocíclico o heterocíclico de 3 - 7 miembros opcionalmente sustituido con 1 - 5 ocurrencias de R⁵; cada R⁵ se selecciona independientemente entre halógeno, -OCH₃, -OH, -NO₂, -NH₂, -SH, -SCH₃, -NHCH₃, -CN, o alifático C₁₋₂ insustituido, o dos grupos R⁵, junto con el carbono al que están ligados, forman un anillo ciclopropilo; R⁶ es -H o alquilo C₁₋₂ insustituido; y R⁷ es un -CH₂CR₃ o -(CH₂)₂CR₃ donde cada R es independientemente -H o -F; que comprende los pasos de: i) hacer reaccionar un compuesto de la fórmula (2) con una sal de clorhidrato de un compuesto de la fórmula (3) en presencia de agua, un solvente orgánico, una base y un catalizador de metal de transición para generar un compuesto de la fórmula (1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504351P | 2011-07-05 | 2011-07-05 | |
| US201261636296P | 2012-04-20 | 2012-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087069A1 true AR087069A1 (es) | 2014-02-12 |
Family
ID=46513874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102438A AR087069A1 (es) | 2011-07-05 | 2012-07-05 | Procesos e intermediarios para producir azaindoles |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8513414B2 (es) |
| EP (2) | EP3141548B9 (es) |
| JP (3) | JP2014520815A (es) |
| KR (1) | KR20140058547A (es) |
| CN (2) | CN106432311A (es) |
| AR (1) | AR087069A1 (es) |
| AU (1) | AU2012279046B2 (es) |
| BR (1) | BR112014000115A2 (es) |
| CA (1) | CA2839937C (es) |
| DK (1) | DK3141548T3 (es) |
| ES (1) | ES2804528T3 (es) |
| MX (1) | MX2013015147A (es) |
| NZ (2) | NZ714502A (es) |
| PL (1) | PL3141548T3 (es) |
| PT (1) | PT3141548T (es) |
| RU (1) | RU2014103806A (es) |
| TW (1) | TW201321378A (es) |
| WO (1) | WO2013006634A2 (es) |
| ZA (1) | ZA201400049B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101216372B1 (ko) * | 2004-03-30 | 2013-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌 |
| KR102050712B1 (ko) | 2009-06-17 | 2019-12-02 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| DK3141548T3 (da) | 2011-07-05 | 2020-07-06 | Vertex Pharma | Fremgangsmåder og mellemprodukter til fremstilling af azaindoler |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2014201332A1 (en) | 2013-06-14 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical combinations useful for treating rheumatoid arthritis |
| KR20160045070A (ko) | 2013-08-22 | 2016-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 동위원소 풍부 아자인돌 |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| PL3068776T3 (pl) | 2013-11-13 | 2019-10-31 | Vertex Pharma | Inhibitory replikacji wirusów grypy |
| KR102338461B1 (ko) | 2013-11-13 | 2021-12-13 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제 억제제의 제조 방법 |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| EP3362451B1 (en) * | 2015-12-09 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN105523986A (zh) * | 2015-12-30 | 2016-04-27 | 江汉大学 | 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法 |
| HRP20210145T1 (hr) * | 2016-09-09 | 2021-03-05 | F. Hoffmann - La Roche Ag | Postupak za dobivanje 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-b;3',4'-d]pirola |
| LT3558321T (lt) | 2016-12-23 | 2023-05-10 | Felicitex Therapeutics, Inc. | Chinolinų dariniai kaip dyrk1a ir (arba) dyrk1b kinazių inhibitoriai |
| CN113242859B (zh) * | 2018-12-24 | 2023-04-14 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
| CN113121452A (zh) * | 2021-05-10 | 2021-07-16 | 甘肃堡昌化工有限公司 | 一种硫酸法尿嘧啶的精制工艺 |
| CN113851244A (zh) * | 2021-09-18 | 2021-12-28 | 浙江爱索拓科技有限公司 | 一种含放射性同位素碳-14废水的处理方法 |
| CN113896716A (zh) * | 2021-10-27 | 2022-01-07 | 浙江爱索拓科技有限公司 | 一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| AU2001237041B9 (en) | 2000-02-17 | 2005-07-28 | Amgen Inc. | Kinase inhibitors |
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP1506189A1 (en) | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| KR20050004214A (ko) | 2002-05-31 | 2005-01-12 | 에자이 가부시키가이샤 | 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물 |
| WO2005033072A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
| EP1712549B1 (en) | 2004-01-30 | 2018-04-11 | Nagase & Company, Ltd. | Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same |
| CN100569772C (zh) * | 2004-03-30 | 2009-12-16 | 沃泰克斯药物股份有限公司 | 用作jak和其它蛋白激酶抑制剂的氮杂吲哚 |
| KR101216372B1 (ko) | 2004-03-30 | 2013-01-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌 |
| WO2006038001A1 (en) * | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| US8921376B2 (en) | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| CN104650077A (zh) | 2006-01-17 | 2015-05-27 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| CN101374839A (zh) * | 2006-01-17 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| CN101541783B (zh) * | 2006-06-30 | 2014-10-01 | 苏尼西斯制药有限公司 | 吡啶酮基pdk1抑制剂 |
| RU2448109C2 (ru) * | 2006-08-08 | 2012-04-20 | Чугаи Сейяку Кабусики Кайся | Производное пиримидина в качестве ингибитора pi3k и его применение |
| EP2102210B1 (en) | 2006-12-14 | 2011-02-09 | Vertex Pharmceuticals Incorporated | Compounds useful as protein kinase inhibitors |
| HRP20120476T1 (hr) * | 2007-11-05 | 2012-06-30 | Novartis Ag | Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza |
| CA2713710A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| KR102050712B1 (ko) | 2009-06-17 | 2019-12-02 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| DK3141548T3 (da) | 2011-07-05 | 2020-07-06 | Vertex Pharma | Fremgangsmåder og mellemprodukter til fremstilling af azaindoler |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP2776036A1 (en) | 2011-11-07 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
| KR20160045070A (ko) | 2013-08-22 | 2016-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 동위원소 풍부 아자인돌 |
-
2012
- 2012-07-03 DK DK16190960.1T patent/DK3141548T3/da active
- 2012-07-03 US US13/541,504 patent/US8513414B2/en not_active Expired - Fee Related
- 2012-07-03 RU RU2014103806/04A patent/RU2014103806A/ru not_active Application Discontinuation
- 2012-07-03 JP JP2014519264A patent/JP2014520815A/ja not_active Withdrawn
- 2012-07-03 EP EP16190960.1A patent/EP3141548B9/en active Active
- 2012-07-03 MX MX2013015147A patent/MX2013015147A/es not_active Application Discontinuation
- 2012-07-03 AU AU2012279046A patent/AU2012279046B2/en not_active Ceased
- 2012-07-03 NZ NZ714502A patent/NZ714502A/en not_active IP Right Cessation
- 2012-07-03 CA CA2839937A patent/CA2839937C/en active Active
- 2012-07-03 CN CN201610811795.3A patent/CN106432311A/zh active Pending
- 2012-07-03 EP EP12735411.6A patent/EP2729465A2/en not_active Withdrawn
- 2012-07-03 KR KR1020147003091A patent/KR20140058547A/ko not_active Withdrawn
- 2012-07-03 CN CN201280036682.0A patent/CN103702998A/zh active Pending
- 2012-07-03 ES ES16190960T patent/ES2804528T3/es active Active
- 2012-07-03 BR BR112014000115A patent/BR112014000115A2/pt not_active IP Right Cessation
- 2012-07-03 PT PT161909601T patent/PT3141548T/pt unknown
- 2012-07-03 PL PL16190960T patent/PL3141548T3/pl unknown
- 2012-07-03 NZ NZ619699A patent/NZ619699A/en not_active IP Right Cessation
- 2012-07-03 WO PCT/US2012/045431 patent/WO2013006634A2/en not_active Ceased
- 2012-07-04 TW TW101124076A patent/TW201321378A/zh unknown
- 2012-07-05 AR ARP120102438A patent/AR087069A1/es unknown
-
2013
- 2013-07-12 US US13/940,421 patent/US8796453B2/en not_active Expired - Fee Related
-
2014
- 2014-01-06 ZA ZA2014/00049A patent/ZA201400049B/en unknown
- 2014-06-25 US US14/314,158 patent/US8946425B2/en active Active
- 2014-12-15 US US14/570,044 patent/US9090614B2/en not_active Expired - Fee Related
-
2015
- 2015-06-17 US US14/741,499 patent/US20150284388A1/en not_active Abandoned
-
2016
- 2016-07-22 JP JP2016144361A patent/JP2017002067A/ja not_active Withdrawn
-
2018
- 2018-07-19 JP JP2018135847A patent/JP6761448B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087069A1 (es) | Procesos e intermediarios para producir azaindoles | |
| AR124483A2 (es) | Compuestos heterocíclicos útiles como inhibidores de pdk1 | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR124117A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR105820A1 (es) | Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
| ES2677919T3 (es) | Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR095217A1 (es) | Métodos para síntesis estereoselectiva de análogos de nucleósidos sustituidos | |
| AR099995A1 (es) | Piridilamidinas fungicidas | |
| MX386187B (es) | Compuestos de benzo[b]tiofeno como agonistas de sting. | |
| AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
| AR092869A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| CU20180144A7 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| AR093579A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| AR088327A1 (es) | Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes | |
| AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR090203A1 (es) | Compuestos heterobiciclicos como inhibidores de pde10 | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |